Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839799 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01839799 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 32 participants.
The verdict
NCT01839799, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
Interventions
- RADIATION Chemoradiation
- DRUG Gemcitabine
- DRUG FOLFIRINOX
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839799
The ClinicalTrials.gov registry entry for NCT01839799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Chemoradiation is the first listed.
NCT01839799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839799 about?
NCT01839799 is a clinical study titled "A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma". Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
What is the current status of trial NCT01839799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2013-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01839799?
The interventions under investigation include: Chemoradiation (RADIATION), Gemcitabine (DRUG), FOLFIRINOX (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT01839799?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.